Efficacy of original bacterial lysate in COPD affected by comorbidity: pharmacoeconomic aspect
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that is one of the major causes of disability and mortality of patients. Objective of the study: clinical, pharmacological and pharmacoeconomic study of the effect of oral bacterial lysate (BL) - pathogens of respiratory tract infections on the duration of the stable course of COPD and hospitalization rate in patients with different risk factors and comorbidity - the presence of chronic kidney disease (CKD) and cardiovascular disease (CVD). Methods of the study: clinical, pharmacological and statistical research methods: retrospective review of inpatients' records, assessment of the patients' quality of life, identifying subgroups of patients with cluster analysis, pharmacoeconomic ABC/VEN analysis of drugs used to treat COPD, the most financially intensive drugs were determined. Determination of current and expected drug treatment practice for COPD, cost-effectiveness analysis, pharmacoeconomic assessment of use of BL in the complex pharmacotherapy for COPD of moderate severity was carried out to analyse the costs and impact on the budget. Results and discussions: the investigational BL prolonged the duration of stable course of the disease in patient clusters of different comorbidities, but along with this significantly increased the period until the next hospitalization due to exacerbation of COPD only in patients with concomitant CKD. Conclusions: the inclusion of oral BL in the pharmacotherapy regimen for COPD results in the reduction of financial costs (by 14% per patient a year) while relieving the symptoms of COPD and improving the patients' quality of life.